Michael Loguidice, MD
Clinical Cardiac Electrophysiology · Little Rock, ARNPI 1134564891
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 61.4% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $12,733, 5.3 times the $2,420 reported in 2019.
Across 467 payments — averaging $61.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Boston Scientific$6K
- Medtronic$4K
- Elutia, Inc.$476
- Atricure, Inc.$441
- Pfizer$412
- plus $596 from 12 others
Across 2 payments — averaging $32.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$65
What the payments were for
- Consulting fees$5,40019%
- Travel & lodging$10,85938%
- Food & beverage$11,27839%
- Education$1,0734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 330 | $17,552 |
| Boston Scientific | 31 | $5,620 |
| Medtronic(2 entities) | 31 | $3,512 |
| Elutia, Inc. | 23 | $476 |
| Atricure, Inc. | 6 | $441 |
| Pfizer | 26 | $412 |
| Biosense Webster, Inc. | 1 | $149 |
| Cardiva Medical, Inc. | 3 | $145 |
| Johnson & Johnson | 5 | $91 |
| Actelion Pharmaceuticals US, Inc. | 1 | $39 |
| Merck | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $37 |
| Abiomed | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$7,122
- AVEIR$3,299
- Farapulse$2,349
- GENERAL - THERAPIES$1,265
- AMPLATZER AMULET$1,010
- EVERA MRI XT DR SURESCAN$849
- ENSITE$526
- Micra$453
- HeartMate 3 Left Ventricular Dev$424
- Confirm Rx$321
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$316
- ENSITE PRECISION$235
- ATRICLIP LAA EXCLUSION SYSTEM$180
- Assurity Pacemaker$169
- Carto 3$149
- Ensite Cardiac Mapping System$146
- AURORA EV-ICD MRI SURESCAN$140
- GALLANT$135
- Quadra Allure MP RF CRT Pacemkr$134
- AFFERA MAPPING SYSTEM$115
How this compares
$28,610 in reported general payments places this provider in the 55th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
See all clinical cardiac electrophysiology providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 547 | $369,183 |
| XareltoRivaroxaban | 82 | $62,573 |
| EntrestoSacubitril/Valsartan | 56 | $35,749 |
| Dofetilide | 135 | $23,069 |
| MultaqDronedarone Hcl | 18 | $19,375 |
| Mexiletine Hcl | 69 | $3,998 |
| Metoprolol Succinate | 262 | $3,080 |
| Propafenone Hcl ErPropafenone Hcl | 24 | $2,586 |
| Flecainide Acetate | 30 | $1,915 |
| Nifedipine ErNifedipine | 26 | $1,086 |
| Metoprolol Tartrate | 210 | $1,026 |
| Amiodarone Hcl | 84 | $1,022 |
| Pantoprazole Sodium | 195 | $965 |
| Potassium Chloride | 42 | $930 |
| Propafenone Hcl | 21 | $908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $412 | $369,183547 claims |
| Johnson & JohnsonXarelto | $91 | $62,57382 claims |
| NovartisEntresto | $13 | $35,74956 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
Other clinical cardiac electrophysiology in Little Rock
- Monica LoLittle Rock$190K
- Sudarone ThihalolipavanLittle Rock$77K
- Prabhat HebbarLittle Rock$75K
- Gerald GreerLittle Rock$41K
- Risheek KaulLittle Rock$38K
- Breck SandvallLittle Rock$23K
- Brian NorrisLittle Rock$18K
- Thomas WallaceLittle Rock$14K
- Subodh DevabhaktuniLittle Rock$9K
- van de BruynLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.